The life-expectancy for women has increased significantly in the 20th century, although the time of onset of menopause has not. Almost a third of a woman's life is now postmenopausal and therefore many postmenopausal women consider using hormone replacement therapy (HRT) to improve their quality of life. Most cases of endometrial carcinoma arise in postmenopausal women and this raises concern among patients and clinicians with regard to the safety of HRT in this age group. Whenever the use of HRT is considered, a careful consideration of the actual benefit in terms of symptom relief and quality of life must be balanced against the risks for each individual woman. This review discusses the effects of HRT on the endometrium and the evidence regarding HRT use and risk of endometrial cancer.
RossouwJE, AndersonGL, PrenticeRL, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–33
2.
PikeMC, PetersRK, CozenW, Estrogen–progestin replacement therapy and endometrial cancer. J Natl Cancer Inst1997;89:1110–6
3.
HornLC, DietelM, EinenkelJ. Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis. Eur J Obstet Gynecol Reprod Biol2005;122:4–12
4.
HammarM, ChristauS, Nathorst-BoosJ, RudT, GarreK. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol1998;105:904–11
5.
MirkinS, NavarroF, ArcherDF. Hormone therapy and endometrial angiogenesis. Climacteric2003;6:273–7
6.
LockwoodCJ, RunicR, WanL, KrikunG, DemopolousR, SchatzF. The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraception. Hum Reprod2000;15(Suppl. 3):144–51
7.
VincentAJ, ZhangJ, OstorA, Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding?Hum Reprod2002;17:1189–98
8.
HickeyM, CreweJ, GoodridgeJP, Menopausal hormone therapy and irregular endometrial bleeding: a potential role for uterine natural killer cells?J Clin Endocrinol Metab2005;90:5528–35
9.
CheginiN, LuoX, PanQ, Rhoton-VlasakA, ArcherDF. Endometrial expression of epithelial neutrophil-activating peptide-78 during the menstrual cycle or in progestin-only contraceptive users with breakthrough bleeding and the influence of doxycycline therapy. Hum Reprod2007;22:427–33
10.
LiR, LuoX, PanQ, Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication in irregular uterine bleeding. Hum Reprod2006;21:2555–63
11.
ArcherDF, PickarJH. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data. Climacteric2002;5:45–59
12.
ElliottJ, ConnorME, LashenH. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynecol Scand2003;82:1112–9
13.
ArcherDF, LoboRA, LandHF, PickarJH. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause1999;6:201–8
14.
Smith-BindmanR, KerlikowskeK, FeldsteinVA, Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA1998;280:1510–7
AndersonGL, JuddHL, KaunitzAM, Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA2003;290:1739–48
20.
BeralV, BullD, ReevesG. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet2005;365:1543–51
LangerRD, LandgrenBM, RymerJ, HelmondFA. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol2006;195:1320–7
23.
EttingerB, KenemansP, JohnsonSR, Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol2008;112:653–9
24.
WierikEJ, HendricksPT, Boerstoel-StreeflandM. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study. Climacteric2004;7:197–209
JohnsonSR, EttingerB, MacerJL, EnsrudKE, QuanJ, GradyD. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol2005;105:779–87
27.
LundstromE, BygdesonM, SvaneG, AzavedoE, von SchoultzB. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric2007;10:249–56
28.
CreasmanWT, HendersonD, HinshawW, Clarke-PearsonDL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol1986;67:326–30
29.
LeeRB, BurkeTW, ParkRC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol1990;36:189–91
30.
ChapmanJA, DiSaiaPJ, OsannK, RothPD, GillotteDL, BermanML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol1996;175:1195–200
31.
SurianoKA, McHaleM, McLarenCE, LiKT, ReA, DiSaiaPJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol2001;97:555–60
Al TalibA, GilbertL, ArseneauJ. Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy. Saudi Med J2008;29:1044–7
